Effect of bariatric-metabolic surgery combined with continuity of care on the remission of metabolic diseases in patients with obesity.
Abstract
Objective
this study aimed to evaluate the impact of bariatric-metabolic surgery combined with continuity of care on the remission of metabolic diseases in obese patients.
Methods
clinical data from 120 obese patients treated between January 2021 and January 2023 were retrospectively analyzed. All patients underwent bariatric-metabolic surgery and received postoperative continuity of care. Body mass index (BMI), percentage of excess weight loss (%EWL), percentage of total weight loss (%TWL), glycemic indices, lipid profiles, and uric acid (UA) levels were assessed at 3, 6, and 12 months postoperatively. Remission rates of metabolic diseases and nursing satisfaction were evaluated at 12 months.
Results
BMI decreased significantly at all postoperative time points (p < 0.05). Both %TWL and %EWL increased progressively over time (p < 0.05). FBG, HbA1c, UA, TC, TG, and LDL-C levels declined significantly, whereas HDL-C increased throughout follow-up (all p < 0.05). At 12 months, remission rates were 69.57 % for hypertension, 94.62 % for hyperuricemia, 80.00 % for type 2 diabetes mellitus, and 79.55 % for hyperlipidemia. Overall nursing satisfaction was 89.17 %.
Conclusion
bariatric-metabolic surgery combined with continuity of care effectively reduces body weight, improves glucose, lipid, and UA metabolism, promotes remission of metabolic diseases, and is associated with high patient satisfaction.